<DOC>
	<DOCNO>NCT03088072</DOCNO>
	<brief_summary>This single arm , open label , single site study assess feasibility post-procedural edoxaban therapy atrial fibrillation ( AF ) patient clinically indicate WATCHMAN leave atrial appendage ( LAA ) closure .</brief_summary>
	<brief_title>A Pilot Study Edoxaban Patients With Non-Valvular Atrial Fibrillation Left Atrial Appendage Closure</brief_title>
	<detailed_description>This single site , PI initiate pilot study . This study enroll 75 patient clinically indicate Left Atrial Appendage ( LAA ) closure commercially available WATCHMAN device . Subjects enrol meet study inclusion/exclusion criterion successful LAA closure . All patient enrol study receive 6 week edoxaban therapy . At 6 week post LAA closure Transesophageal Echocardiography ( TEE ) perform . If result acceptable , edoxaban discontinue patient treat dual antiplatelet therapy ( aspirin clopidogrel ) 6 month follow-up . After study completion , patient may treat aspirin monotherapy accord FDA instruction use WATCHMAN device , accord operator discretion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>The patient document paroxysmal , persistent , permanent nonvalvular AF ( i.e. , patient diagnose rheumatic mitral valve disease ) . LAA closure WATCHMAN device plan The patient fulfill FDA indication WATCHMAN LAA closure The patient legal representative able understand willing provide write informed consent participate trial The patient able willing return require followup visit examination . The patient 18 year age old Conditions atrial fibrillation require anticoagulation ( e.g. , prosthetic heart valve ) Stroke within previous 7 day Hypersensitivity edoxaban Moderate severe mitral stenosis A need aspirin dose &gt; 81 mg day A need ongoing treatment dual antiplatelet therapy aspirin clopidogrel A need ongoing treatment ticagrelor prasugrel No LAA closure device implant procedure Procedural complication LAA closure ( e.g. , stroke , systemic embolism , bleeding , vascular complication [ e.g. , groin hematoma &gt; 10cm , AV fistula , pseudoaneurysm ) , serious pericardial effusion ) Planned surgery invasive procedure within 6Â±2 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Edoxaban</keyword>
	<keyword>WATCHMAN device</keyword>
</DOC>